Trinity Biotech (TRIB) EBT (2009 - 2024)

Trinity Biotech has disclosed EBT across 16 years of filings, most recently posting -$15.8 million for Q4 2024.

• EBT for Q4 2024 came in at -$15.8 million, down 186.96% year-over-year; the trailing twelve-month figure through Dec 2024 was -$30.7 million (up 16.8% YoY), and the FY2025 annual result was -$37.2 million, down 20.98% from the prior year.
• EBT came in at -$15.8 million for Q4 2024 at Trinity Biotech, down from -$4.8 million in the prior quarter.
• In the past five years, EBT ranged from a high of $10.3 million in Q3 2020 to a low of -$18.6 million in Q2 2023.
• The 5-year median for EBT is -$5.1 million (2023), against an average of -$4.1 million.
• Across the five-year window, EBT surged 283.53% in 2020 and slumped 7829.69% in 2022, its largest moves.
• Trinity Biotech's EBT stood at $10.3 million in 2020, then sank by 123.6% to -$2.4 million in 2021, then sank by 329.53% to -$10.4 million in 2022, then soared by 47.21% to -$5.5 million in 2023, then plunged by 186.96% to -$15.8 million in 2024.
• The last three EBT figures came in at -$15.8 million (Q4 2024), -$4.8 million (Q3 2024), and -$6.9 million (Q2 2024), per Business Quant data.